SI1789036T1 - 5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofaga - Google Patents

5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofaga

Info

Publication number
SI1789036T1
SI1789036T1 SI200531283T SI200531283T SI1789036T1 SI 1789036 T1 SI1789036 T1 SI 1789036T1 SI 200531283 T SI200531283 T SI 200531283T SI 200531283 T SI200531283 T SI 200531283T SI 1789036 T1 SI1789036 T1 SI 1789036T1
Authority
SI
Slovenia
Prior art keywords
benzyloxyphenylthio
imidazolidin
fur
dione
inhibitors
Prior art date
Application number
SI200531283T
Other languages
English (en)
Slovenian (sl)
Inventor
Fude Yang
Original Assignee
Quest Pharmaceutical Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Pharmaceutical Services filed Critical Quest Pharmaceutical Services
Publication of SI1789036T1 publication Critical patent/SI1789036T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200531283T 2004-08-19 2005-08-17 5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofaga SI1789036T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60273604P 2004-08-19 2004-08-19
EP05786673A EP1789036B1 (en) 2004-08-19 2005-08-17 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase
PCT/US2005/029259 WO2006023562A2 (en) 2004-08-19 2005-08-17 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase

Publications (1)

Publication Number Publication Date
SI1789036T1 true SI1789036T1 (sl) 2011-09-30

Family

ID=35968136

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531283T SI1789036T1 (sl) 2004-08-19 2005-08-17 5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofaga

Country Status (16)

Country Link
US (1) US7179831B2 (https=)
EP (1) EP1789036B1 (https=)
JP (1) JP5042833B2 (https=)
KR (1) KR101197325B1 (https=)
CN (1) CN101014338B (https=)
AT (1) ATE508744T1 (https=)
AU (1) AU2005277432B2 (https=)
BR (1) BRPI0514470B8 (https=)
CA (1) CA2577430C (https=)
DK (1) DK1789036T3 (https=)
ES (1) ES2364068T3 (https=)
MX (1) MX2007001940A (https=)
NZ (1) NZ553258A (https=)
RU (1) RU2391339C2 (https=)
SI (1) SI1789036T1 (https=)
WO (1) WO2006023562A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084485A2 (en) * 2006-01-13 2007-07-26 Battelle Memorial Institute Markers for assessing copd-related diseases
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
MX387820B (es) * 2016-08-19 2025-03-18 Foresee Pharmaceuticals Co Ltd Composición farmacéutica y métodos de usos.
US10532102B2 (en) * 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
JP6934012B2 (ja) * 2016-09-23 2021-09-08 科研製薬株式会社 （ｒ）‐５‐（３，４‐ジフルオロフェニル）‐５‐［（３‐メチル‐２‐オキソピリジン‐１（２ｈ）‐イル）メチル］イミダゾリジン‐２，４‐ジオンの製造方法およびその製造のための中間体
SI3793995T1 (sl) 2018-05-15 2024-05-31 Foresee Pharmaceuticals Usa, Inc. Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe
CA3158234A1 (en) * 2019-11-14 2021-05-20 Foresee Pharmaceuticals Co., Ltd. Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
EP4351566A4 (en) * 2021-06-08 2025-04-23 Foresee Pharmaceuticals USA, Inc. SAFE ADMINISTRATION OF MMP-12 INHIBITOR
RU2766551C1 (ru) * 2021-07-19 2022-03-15 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) 5-(4-хлорфенил)-3-((4-хлорфенил)амино)-5-(фенилтио)фуран-2(5н)-он, обладающий противомикробной активностью

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1150975A1 (en) 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6352976B1 (en) * 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
RU2150469C1 (ru) * 1999-06-01 2000-06-10 Уфимский государственный нефтяной технический университет Способ получения 2-(фурил-2)-1,3-имидазолидинов
EP1288199A4 (en) 2000-04-28 2005-10-12 Shionogi & Co INHIBITORS OF MMP-12
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US6890915B2 (en) 2001-05-25 2005-05-10 Bristol-Myers Squibb Pharma Company Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
AU2003282920A1 (en) * 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)

Also Published As

Publication number Publication date
EP1789036A2 (en) 2007-05-30
ES2364068T3 (es) 2011-08-24
RU2391339C2 (ru) 2010-06-10
KR20070045330A (ko) 2007-05-02
DK1789036T3 (da) 2011-06-27
RU2007105822A (ru) 2008-09-27
CN101014338B (zh) 2010-06-16
WO2006023562A2 (en) 2006-03-02
WO2006023562A3 (en) 2006-04-20
WO2006023562B1 (en) 2006-06-22
US7179831B2 (en) 2007-02-20
AU2005277432A1 (en) 2006-03-02
AU2005277432B2 (en) 2011-11-24
NZ553258A (en) 2011-02-25
EP1789036B1 (en) 2011-05-11
US20060041000A1 (en) 2006-02-23
HK1107774A1 (en) 2008-04-18
MX2007001940A (es) 2007-07-24
KR101197325B1 (ko) 2012-11-05
EP1789036A4 (en) 2008-08-27
JP5042833B2 (ja) 2012-10-03
BRPI0514470A (pt) 2008-06-10
BRPI0514470B8 (pt) 2021-07-20
CA2577430A1 (en) 2006-03-02
JP2008510701A (ja) 2008-04-10
CA2577430C (en) 2010-12-07
CN101014338A (zh) 2007-08-08
ATE508744T1 (de) 2011-05-15
BRPI0514470B1 (pt) 2021-01-05

Similar Documents

Publication Publication Date Title
IL176571A0 (en) Substituted azole derivatives, compositions, and methods of use
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
ATE452631T1 (de) N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
NO20081636L (no) FAP - inhibitorer
TW200735865A (en) Compositions of an anticonvulsant and methods of using the same for reversing weight gain
DE60325032D1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
NO20043645L (no) Sykloalkylinhibitorer av kaliumkanal-funksjon
LTPA2013018I1 (lt) 4-oksochinolino junginiai ir jų, kaip živ inregrazės inhibitorių, panaudojimas
FR2835186B1 (fr) Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
DK2094107T3 (da) Mykotoksin-reducerende sammensætning
IL185541A0 (en) Benzazole derivatives, compositions, and methods of use as b- secretase inhibitors
DK1776011T3 (da) Fungicid sammensætning, indeholdende et syreamidderivat
NO20053340D0 (no) Substituerte dihydropyrano-indol-3,4-dion-derivater som inhibitorer for plasmigogenaktivator-1 (CPAI-1).
NO20082298L (no) Kaliumkanalinhibitorer
EP1559433A4 (en) STABILIZED COMPOSITION
TW200715969A (en) Fungicidal active-compound combination
MX2007008136A (es) Metodo para invertir la resistencia multiple en celulas animales.
EP1667685A4 (en) -QUINAZOLINE-POTASSIUM CHANNEL INHIBITORS
SI1789036T1 (sl) 5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofaga
AU2003234925A1 (en) TGF-Alpha EXPRESSION INHIBITORS
DK1499197T3 (da) Törgærsammensætning
MX2007002917A (es) Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.
EP1767200A4 (en) MEDIUM AGAINST SKIN AGING
AU2003215158A1 (en) 2-(5-(5-carbamimidoyl-1h-heteroaryl))-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer